Description
The National Cancer Institute (NCI) is issuing a Request for Applications (RFA) to fund a Glioblastoma Therapeutics Network (GTN) under a U19 Cooperative Agreement. The network will consist of up to four cross‑cutting research teams that will advance novel or repurposed therapeutic agents for adult glioblastoma (GBM) from late pre‑clinical work through Phase 0/1 pilot clinical trials. Successful candidates must demonstrate the ability to develop agents that cross the blood‑brain barrier, conduct IND‑enabling studies, and initiate early‑phase human testing. The award provides up to $700,000 per U19 award (total estimated funding $4.4 M) and expects strong collaboration with NCI program staff, data sharing, and adherence to NIH policies. Applications are limited to one per institution and are open to a broad range of U.S. entities (non‑profits, for‑profit, academic, government, etc.). The submission window opens 1 Sept 2026 and closes 11 Jan 2027.